It’s been almost a decade since the US Food and Drug Administration (FDA) approved the first checkpoint inhibitor, Bristol Myers Squibb’s YERVOY® (ipilimumab) in 2011. In recent years, the number of clinical trials involving checkpoint inhibitors and other immuno-oncology (IO) therapies has been increasing as Sponsors investigate their use in combination with one another, with radiotherapy, chemotherapies, targeted therapies, cancer vaccines and oncolytic viruses.
Despite the benefits that these combination approaches promise to patients, the sheer number of potential therapies, combinations, and administration regimens poses challenges for Sponsors. In this free webinar, the featured speakers will highlight the issues that Sponsors face in planning and executing combination IO therapy trials and suggest strategies to deliver a more intentional approach and choice of combinations for hypothesis testing in their IO trials.
The session will end in an open question and answer discussion.
Jennifer Harris, Vice President, Clinical Development Oncology and Global Head of Immuno-Oncology, Syneos Health
Jennifer Harris serves as head for the Immuno-Oncology (IO) business at Syneos Health. In this role, Harris is responsible for IO strategy and scientific support for the project portfolio. Throughout her 25-year career focused in oncology, Harris has also held clinical positions at major academic centers, the NIH clinical center and held scientific roles within biotech and large pharma. Over the past 10 years, Harris has focused primarily on the rapidly expanding field of immuno-oncology. Her pharma experience includes work at Merck & Co, GSK, Dendreon and other oncology focused biotech. Harris earned a Doctor of Pharmacy and Bachelor of Science degree in Pharmacy from the University of North Carolina.Message Presenter
Jessica Lee, Managing Director, Consulting, Syneos Health
Jessica B. Lee, PhD is a managing director in Syneos Health Consulting’s Commercial Advisory Group. She has over ten years of experience working in oncology and assisting manufacturers to commercialize oncology therapeutics. She specializes in assisting clients with market opportunity assessments, indication prioritization, therapeutic area growth strategies, portfolio strategies, and product launch and commercialization strategies. Lee has a PhD in Immunology from Johns Hopkins University’s School of Medicine.Message Presenter
Francesca Zolezzi, Director, Molecular Profiling, Translational Sciences, Syneos Health
Dr. Francesca Zolezzi is the director of integrated biomarker solutions in the Translational Sciences Early Phase Operations, Syneos Health. She proposes her knowledge and the relevant “omics” platforms to help clients to advance their clinical or preclinical programs in drug development. Zolezzi obtained her bachelor’s degree in biology from the University of Padova, Italy and a postgraduate degree in Medical Genetics at the University of Verona, Italy.Message Presenter
Who Should Attend?
This webinar is for professionals who are involved in:
- Clinical Development
- Market Access
- Medical Affairs
- Payer Strategy
- Real World Evidence
What You Will Learn
- Challenges and questions to consider, including complexity in trial design, competition for patients and sites, the potential for overlapping toxicities, the selection of biomarkers, and commercial risks as the standard of care (SOC) evolves rapidly.
- Recommendations to streamline development and support commercial success.
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com.